Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Sol-Gel Technologies Ltd. (SLGL)

Bicycle Therapeutics PLC Sponsored ADR and Sol-Gel Technologies Ltd. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Sol-Gel Technologies Ltd. are of similar size ($199.4M and $198.9M). Bicycle Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 217.4% against −92.5%. Bicycle Therapeutics PLC Sponsored ADR has the higher net margin (−311.1% vs −910.1%) and the lower return on invested capital (−64,747.5% vs −6,630.2%). Across the 16 metrics below, Bicycle Therapeutics PLC Sponsored ADR leads on 12 and Sol-Gel Technologies Ltd. on 4.

Valuation

Metric BCYC SLGL Biotechnology median
P/E n/m n/m 7.88
P/S 4.21 121.82 11.47
P/B 0.50 4.55 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 1.13 n/m 0.74
EV/Sales (3.78) 95.38 10.73
Earnings yield (73.98%) (8.44%) (28.84%)
Free cash flow yield (80.86%) (9.73%) (23.03%)

Profitability

Metric BCYC SLGL Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (343.60%) (986.96%) 0.00%
Net margin (311.11%) (910.14%) 0.00%
Free cash flow margin (340.29%) (1,185.18%) 0.00%
Return on equity (32.30%) (40.85%) (57.72%)
Return on assets (26.47%) (35.11%) (49.22%)
Return on invested capital (64,747.54%) (6,630.24%) 0.00%

Growth

Metric BCYC SLGL Biotechnology median
Revenue growth (TTM) 217.44% (92.50%) 5.64%
EPS growth (last fiscal year) (8.97%) 42.37% —
Revenue growth, 5-year CAGR 47.52% 17.19% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.08 10.37 4.73
Net debt to EBITDA 2.61 3.23 0.96

Dividend

Metric BCYC SLGL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCYC SLGL Biotechnology median
Market cap 199.41m 198.86m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack